A Compound Heterozygosis of Two Novel Mutations in vWF Exacerbates vWD in a Chinese Pedigree

被引:0
作者
Hu, Jiajia [1 ]
Yu, He [1 ]
Wang, Wuchao [2 ]
Li, Jinfang [1 ]
Xu, Qinzhu [1 ]
Rong, Jiang [1 ]
Lu, Songsong [1 ,3 ]
机构
[1] Peking Univ Peoples Hosp, Dept Clin Lab, Beijing, Peoples R China
[2] Peking Univ Peoples Hosp, Dept Emergency, Beijing, Peoples R China
[3] Peking Univ Peoples Hosp, Dept Clin Lab, 11 Xizhimen South St, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
vWF; vWD; genetic analysis; coagulation; compound heterozygous mutations; VON-WILLEBRAND-FACTOR; DISEASE; VARIANTS; BIOLOGY; BINDING; GENE;
D O I
10.7754/Clin.Lab.2023.230707
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: von Willebrand disease (vWD), caused by mutations in the von Willebrand factor (vWF) coding gene, is a disease characterized by abnormal coagulation activity and a severe tendency for hemorrhage. Therefore, identifying mutations in vWF is important for diagnosing congenital vWD. Methods: We studied a 23 -year -old male vWD patient and his parents. Clotting methods were used to determine activated partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen (FIB) levels, FVIII activity. Chromogenic substrate method was used to determine vWF antigen and activity. The platelet count was determined. Mutations were searched using whole-exome sequencing and certified by Sanger sequencing. Clinical data, including activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen levels, FX activity, FX antigen levels, and the platelet count were collected. A mixing study was performed to eliminate the presence of coagulation factor inhibitors and lupus anticoagulants. Mutations were screened by using whole-exome sequencing (WES) and were verified by using Sanger sequencing. Results: The proband showed severely decreased vWF antigen, vWF activity, and FVIII activity. RIPA (RISTOCETIN-induced platelet aggregation) was 0%. Data from WES showed that the proband carried compound heterozygous variants vWF: NM_000552.5 (c.3213C>A p.Cys1071Ter) and vWF: NM_000552.5 (c.6598+2T>C). The proband's mother carried variant vWF: NM_000552.5 (c.3213C>A p.Cys1071Ter) while the proband's father carried variant vWF: NM_000552.5 (c.6598+2T>C). All laboratory test indexes of the proband's parents, including vWF antigen, vWF activity, and FVIII activity, were within the normal ranges. Conclusions: We identified a compound heterozygosis with two novel mutations in vWF (c.3213C>A, c.6598+2T >C) in a family pedigree, and our results demonstrate that the compound heterozygous mutations probably exacerbate vWD.
引用
收藏
页码:372 / 377
页数:6
相关论文
共 21 条
  • [1] Comparative analysis of type 2b von Willebrand disease mutations: Implications for the mechanism of von Willebrand factor binding to platelets
    Cooney, KA
    Ginsburg, D
    [J]. BLOOD, 1996, 87 (06) : 2322 - 2328
  • [2] Von Willebrand disease mutation spectrum and associated mutation mechanisms
    de Jong, Annika
    Eikenboom, Jeroen
    [J]. THROMBOSIS RESEARCH, 2017, 159 : 65 - 75
  • [3] von Willebrand factor propeptide: biology and clinical utility
    Haberichter, Sandra L.
    [J]. BLOOD, 2015, 126 (15) : 1753 - 1761
  • [4] Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin - but not botrocetin-mediated binding of von Willebrand factor to platelets
    Hillery, CA
    Mancuso, DJ
    Sadler, JE
    Ponder, JW
    Jozwiak, MA
    Christopherson, PA
    Gill, JC
    Scott, JP
    Montgomery, RR
    [J]. BLOOD, 1998, 91 (05) : 1572 - 1581
  • [5] Tissue distribution of factor VIII gene expression in vivo -: A closer look
    Hollestelle, MJ
    Thinnes, T
    Crain, K
    Stiko, A
    Kruijt, JK
    van Berkel, TJC
    Loskutoff, DJ
    van Mourik, JA
    [J]. THROMBOSIS AND HAEMOSTASIS, 2001, 86 (03) : 855 - 861
  • [6] CULTURE OF HUMAN ENDOTHELIAL CELLS DERIVED FROM UMBILICAL VEINS - IDENTIFICATION BY MORPHOLOGIC AND IMMUNOLOGICAL CRITERIA
    JAFFE, EA
    NACHMAN, RL
    BECKER, CG
    MINICK, CR
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1973, 52 (11) : 2745 - 2756
  • [7] A revised model of platelet aggregation
    Kulkarni, S
    Dopheide, SM
    Yap, CL
    Ravanat, C
    Freund, M
    Mangin, P
    Heel, KA
    Street, A
    Harper, IS
    Lanza, F
    Jackson, SP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (06) : 783 - 791
  • [8] Von Willebrand's Disease
    Leebeek, Frank W. G.
    Eikenboom, Jeroen C. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21) : 2067 - 2080
  • [9] Meyer D, 1997, THROMB HAEMOSTASIS, V78, P451
  • [10] The Manifold Cellular Functions of von Willebrand Factor
    Mojzisch, Angelika
    Brehm, Maria A.
    [J]. CELLS, 2021, 10 (09)